Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 Clinical Trial Optional)

The summary for the Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 Clinical Trial Optional): The primary objective of this FOA is to solicit research projects with the aim of elucidating the role of positive affect and related processes in suicidal individuals and evaluating modifiable behavioral and neural targets. Specifically, studies should include clinical populations with high risk of suicide, suicide attempters or acutely suicidal individuals, and may also include non-suicidal patients, high risk individuals in an absence of diagnosis, or healthy control groups. Projects across developmental spectrum are encouraged. Research projects should aim to 1) specify a construct of interest either in terms of research domain criteria: positive valence system (RDoC PVS), or a symptom relevant construct, such as an anhedonia/ anhedonia subtype, cognitive process such as present/future reward decision making, generating reasons for living in the context of anticipation of positive experiences, etc. 2) demonstrate that measures of the construct are reliable and reproducible and engage brain subsystem relevant to positive affect, and/or 3) show active modification of targeted brain system and behavioral measures of the construct through behavioral training or other means such as use of non-invasive neuromodulation, pharmacological or psychosocial therapeutic probes. Behavioral tasks used may include both novel and established tasks within the RDoC positive valence domain (e.g. reward sensitivity, reward valuation, and reward learning) and/or tasks probing components and subconstructs of hedonic and related processes. Use of measures of the dynamic changes in PA is strongly encouraged to further establish co-occurrence with other risk factors and suicidality.

Federal Grant Title:	Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAS-21-215
Type of Funding:	Grant
CFDA Numbers:	93.242
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 16th, 2021
Original Application Deadline:	October 16th, 2021
Posted Date:	April 16th, 2021
Creation Date:	April 16th, 2021
Archive Date:	November 21st, 2021
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	April 16th, 2021

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAS-21-215.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health D...; • Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Re...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...